Kylie Shackleton
Overview
Explore the profile of Kylie Shackleton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
188
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shepherd R, Bradford A, Lieschke M, Shackleton K, Hyatt A
Trials
. 2023 Jun;
24(1):400.
PMID: 37312206
Background: As cancer therapies increase in their complexity, effective communication among patients, physicians, and research staff is critical for optimal clinical trial management. Currently, we understand little about on-trial communication...
2.
Lee J, Burbury K, Underhill C, Harris S, Shackleton K, McBurnie J, et al.
J Telemed Telecare
. 2020 Aug;
28(7):508-516.
PMID: 32811275
Introduction: Regional cancer patients face various barriers in accessing specialist cancer services. Teletrials are a new model of care that utilise communications technologies to enable access to and participation in...
3.
Lammert J, Skandarajah A, Shackleton K, Calder P, Thomas S, Lindeman G, et al.
Asia Pac J Clin Oncol
. 2019 Oct;
16(2):e27-e37.
PMID: 31657879
Objectives: The value of a high-risk surveillance program for mutation carriers and women at high familial breast cancer risk has not been extensively studied. A Breast and Ovarian Cancer Risk...
4.
Page E, Bancroft E, Brook M, Assel M, Hassan Al Battat M, Thomas S, et al.
Eur Urol
. 2019 Sep;
76(6):831-842.
PMID: 31537406
Background: Mutations in BRCA2 cause a higher risk of early-onset aggressive prostate cancer (PrCa). The IMPACT study is evaluating targeted PrCa screening using prostate-specific-antigen (PSA) in men with germline BRCA1/2...
5.
Lok S, Whittle J, Vaillant F, Teh C, Lo L, Policheni A, et al.
Cancer Discov
. 2018 Dec;
9(3):354-369.
PMID: 30518523
Venetoclax, a potent and selective BCL2 inhibitor, synergizes with endocrine therapy in preclinical models of ER-positive breast cancer. Using a phase Ib 3 + 3 dose-escalation and expansion study design,...
6.
Mikropoulos C, Hutten Selkirk C, Saya S, Bancroft E, Vertosick E, Dadaev T, et al.
Br J Cancer
. 2018 Mar;
118(6):e17.
PMID: 29509747
This corrects the article DOI: 10.1038/bjc.2017.429.
7.
Mikropoulos C, Hutten Selkirk C, Saya S, Bancroft E, Vertosick E, Dadaev T, et al.
Br J Cancer
. 2018 Jan;
118(2):266-276.
PMID: 29301143
Background: Prostate-specific antigen (PSA) and PSA-velocity (PSAV) have been used to identify men at risk of prostate cancer (PrCa). The IMPACT study is evaluating PSA screening in men with a...
8.
Skandarajah A, Thomas S, Shackleton K, Chin-Lenn L, Lindeman G, Mann G
Breast
. 2017 Jan;
32:93-97.
PMID: 28107734
Aims: To assess the eligibility, uptake and impediments to tamoxifen use in high-risk women attending a risk management clinic due to family history. Patients And Methods: All patients with a...
9.
Teo Z, Sawyer S, James P, Mitchell G, Trainer A, Lindeman G, et al.
Fam Cancer
. 2013 Mar;
12(4):587-95.
PMID: 23471749
The familial aggregation of breast cancer has been well-described with approximately 25% of breast cancers attributable to inherited mutations in currently known breast cancer susceptibility genes. PALB2 c.3113G>A (p.Trp1038*) is...